Aurobindo Pharma Q4 Review - Below Par Numbers; Progress On New Ventures Key: ICICI Direct

A technician monitoring manufacturing of drugs at Aurobindo Pharma Ltd. (Source: Company website).

Aurobindo Pharma Q4 Review - Below Par Numbers; Progress On New Ventures Key: ICICI Direct


BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Aurobindo Pharma Ltd.'s revenues de-grew 2.5% YoY to Rs 6,002 crore tracking 4.5% YoY decline in U.S. to Rs 2,856 crore and a 6.0% YoY decline in Europe formulations to Rs 1,553 crore.

Rest of world markets also declined, posting 18.8% YoY de-growth to Rs 306 crore.

On the other hand, antiretroviral drugs segment grew 28.7% YoY to Rs 491 crore.

Active pharmaceutical ingredient segment grew 5.1% YoY to Rs 794 crore.

Ebitda margins remained flat, down 13 basis points YoY at 21.2% (our estimate: 20.7%).

Ebitda de-grew 3.2% YoY to Rs 1,275 crore against our estimates of Rs 1,354 crore.

Click on the attachment to read the full report:

ICICI Direct Aurobindo Q4FY21 Result Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.